
Hisashi Hidaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4383552/publications.pdf Version: 2024-02-01



Ηιελεμι Ηισλέλ

#	Article	IF	CITATIONS
1	Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatology Research, 2022, 52, 269-280.	1.8	28
2	Ultrasonography in the diagnosis of complications in patients with portal hypertension. Journal of Medical Ultrasonics (2001), 2022, 49, 347-358.	0.6	1
3	Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Digestive Diseases, 2021, 39, 234-242.	0.8	7
4	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatology Research, 2021, 51, 201-215.	1.8	22
5	A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1233-1239.	0.4	8
6	Evidenceâ€based clinical practice guidelines for liver cirrhosis 2020. Hepatology Research, 2021, 51, 725-749.	1.8	90
7	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. Journal of Gastroenterology, 2021, 56, 593-619.	2.3	158
8	Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. Hepatology Research, 2021, 51, 968-978.	1.8	12
9	Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, , .	1.4	1
10	Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer, 2020, 9, 193-206.	4.2	57
11	<p>Safety and Efi¬€acy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p> . Clinical and Experimental Gastroenterology, 2020, Volume 13, 385-396.	1.0	34
12	Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Scientific Reports, 2020, 10, 17054.	1.6	4
13	Longâ€ŧerm observation in patients with esophageal varices after endoscopic variceal ligation accompanied with 24â€hour pH monitoring. Hepatology Research, 2020, 50, 1255-1263.	1.8	1
14	Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study. Hepatology Research, 2020, 50, 1083-1090.	1.8	12
15	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers, 2020, 12, 293.	1.7	34
16	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Medical Oncology, 2019, 36, 52.	1.2	9
17	Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clinical Gastroenterology and Hepatology, 2019, 17, 1192-1200.	2.4	92

18 Esophagogastric Varices in Liver Cirrhosis. , 2019, , 131-139.

Hisashi Hidaka

#	Article	IF	CITATIONS
19	Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, doubleâ€blind, controlled trial. Hepatology Research, 2018, 48, E107-E116.	1.8	39
20	Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma. Hepatology Research, 2018, 48, E98-E106.	1.8	7
21	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. The Lancet Gastroenterology and Hepatology, 2018, 3, 37-46.	3.7	127
22	Relationship between response to lusutrombopag and splenic volume. World Journal of Gastroenterology, 2018, 24, 5271-5279.	1.4	22
23	Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1402-1407.	0.8	36
24	Three-dimensional computed tomography of portopulmonary venous anastomoses in patients with esophageal varices before treatment. Hepatology Research, 2016, 46, 559-564.	1.8	6
25	Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Research Notes, 2015, 8, 609.	0.6	30
26	Peliosis hepatis disseminated rapidly throughout the liver in a patient with prostate cancer: a case report. Journal of Medical Case Reports, 2015, 9, 194.	0.4	10
27	Intraperitoneal bleeding after balloon-occluded retrograde transvenous obliteration: a case report. Journal of Medical Case Reports, 2015, 9, 62.	0.4	1
28	Field practice study of halfâ€dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. Hepatology Research, 2015, 45, 279-287.	1.8	25
29	Early evaluation of response to sorafenib for hepatocellular carcinoma by duplex <scp>D</scp> oppler ultrasonography. Hepatology Research, 2015, 45, 976-985.	1.8	2
30	Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)–CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report. BMC Research Notes, 2014, 7, 141.	0.6	3
31	Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterology, 2014, 14, 84.	0.8	97
32	The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. Journal of Gastroenterology, 2013, 48, 269-276.	2.3	42
33	Total and viable residual splenic volume measurement after partial splenic embolization by three-dimensional ultrasound. Journal of Medical Ultrasonics (2001), 2013, 40, 417-424.	0.6	1
34	Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2013, 25, 683-689.	0.8	73
35	Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. Journal of Gastroenterology, 2012, 47, 1030-1035.	2.3	27
36	Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial. Journal of Gastroenterology, 2012, 47, 118-126.	2.3	47

Hisashi Hidaka

#	Article	IF	CITATIONS
37	A case of giant intramural hematoma of the esophagus after endoscopic injection sclerotherapy with ligation. Progress of Digestive Endoscopy, 2012, 81, 78-79.	0.0	0
38	Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial. Journal of Gastroenterology, 2011, 46, 1316-1323.	2.3	22
39	Reliability and validity of splenic volume measurement by 3â€Ð ultrasound. Hepatology Research, 2010, 40, 979-988.	1.8	14
40	Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatology Research, 2009, 39, 772-778.	1.8	19
41	Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin. American Journal of Roentgenology, 2007, 188, 480-488.	1.0	314
42	New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. Hepatology Research, 2007, 37, 1011-1017.	1.8	9
43	Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatology Research, 2002, 23, 265-273.	1.8	34